Editorial, Trade Groups Offer Perspective On Null Chondroitin Meta-Analysis
This article was originally published in The Tan Sheet
Executive Summary
Patients should continue taking chondroitin sulfate for osteoarthritis if they perceive a benefit, despite a recent study that found a null effect, according to an accompanying editorial in the April 17 Annals of Internal Medicine
You may also be interested in...
GAIT Authors Seek Further Study Of Moderate-To-Severe Arthritis Sufferers
Authors of the GAIT study have submitted a proposal to further evaluate the effects of glucosamine and chondroitin on osteoarthritis patients by focusing specifically on those with moderate-to-severe pain, according to the study's lead researcher
OTC Prices Make PPI-Aspirin Therapy For CVD Cost-Effective – Study
Using proton pump inhibitors to prevent GI bleeding from low-dose aspirin therapy for cardiovascular health is cost-effective only at OTC prices, according to researchers
OTC Prices Make PPI-Aspirin Therapy For CVD Cost-Effective – Study
Using proton pump inhibitors to prevent GI bleeding from low-dose aspirin therapy for cardiovascular health is cost-effective only at OTC prices, according to researchers